Mandy McNamara
Adult Health · Annapolis, MDNPI 1376904136
Payments from drug & device makers
Across 120 payments — averaging $19.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$490
- Astellas Pharma US Inc$276
- Lilly USA, LLC$254
- Pfizer$203
- AbbVie$165
- Exact Sciences$151
- plus $851 from 24 others
What the payments were for
- Food & beverage$2,29096%
- Education$1004%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 26 | $490 |
| Astellas Pharma US Inc | 10 | $276 |
| Lilly USA, LLC | 14 | $254 |
| Pfizer | 9 | $203 |
| AbbVie | 10 | $165 |
| Exact Sciences | 6 | $151 |
| Merck | 4 | $98 |
| Amgen | 5 | $97 |
| GSK | 4 | $76 |
| Boehringer Ingelheim | 4 | $67 |
| Abbott | 3 | $52 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| BD | 2 | $39 |
| Gilead | 2 | $37 |
| Xeris Pharmaceuticals, Inc. | 2 | $36 |
| Dexcom, Inc. | 1 | $31 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| UCB, Inc. | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Neos Therapeutics, LP | 1 | $22 |
| Lifescan, Inc. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Seqirus USA Inc | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Insulet Corporation | 1 | $15 |
| Novartis | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Philips North America LLC | 1 | $13 |
| Mannkind Corporation | 1 | $12 |
How this compares
$2,390 in reported general payments places this provider in the 80th percentile of 542 adult health providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 63 | $504 |
| Fluticasone Propionate | 41 | $442 |
| Methylprednisolone | 53 | $386 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 20 | $285 |
| Doxycycline Hyclate | 32 | $184 |
| Azithromycin | 35 | $164 |
| Mupirocin | 17 | $159 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 18 | $125 |
| Amlodipine Besylate | 14 | $122 |
| Ciprofloxacin Hcl | 13 | $47 |
| Prednisone | 24 | $29 |
Paid to pharmacies, not to this prescriber.
Other adult health in Annapolis
- Caroline RuhlAnnapolis$315K
- Erin BrimhallAnnapolis$8K
- Lucia NovakCamp Springs$473K
- Joyce MiskovicHighland$264K
- Christopher RobersonBaltimore$180K
- Amit DhirBaltimore$97K
- Angie PriceBaltimore$96K
- Morgan JoliatSykesville$92K
- Brendon BowerBaltimore$64K
- Caitlin NassBaltimore$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.